Melatonin in glioblastoma therapy: clinical promise and mechanistic insights from bench to bedside

Key Points

• Melatonin therapy shows promise in enhancing treatment efficacy for glioblastoma patients, with supportive biomarker evidence.
• Clinical outcomes in glioblastoma patients improved significantly with melatonin, as indicated by recent findings.
• Analysis of various treatment pathways suggests melatonin may modulate glioblastoma progression effectively.
• Highlights the need for comprehensive clinical trials to validate melatonin's effectiveness and safety in glioblastoma therapy.